Guanfacine Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your Guanfacine prescription, you might be wondering: is there an official shortage? The answer as of early 2026 is nuanced. There's no active FDA shortage declaration for Guanfacine, but many patients still experience real difficulties finding their specific dose at local pharmacies. This update explains what's happening, why, and what you can do.

Current Status: No Active FDA Shortage as of Early 2026

The FDA's Drug Shortages Database does not list Guanfacine (either immediate-release or extended-release) as an active shortage as of early 2026. Multiple generic manufacturers produce Guanfacine, and the national supply of this medication is considered adequate.

However, "no national shortage" is not the same as "easily available at every pharmacy." Guanfacine shortages, when they occur, tend to be localized — specific pharmacies, specific strengths, specific geographic areas — rather than nationwide.

Why Patients Are Still Having Trouble Filling Guanfacine

Several real-world factors explain why Guanfacine can be hard to find at your local pharmacy even without a formal shortage:

Stimulant shortage spillover: The ongoing shortage of Adderall and methylphenidate products has pushed more patients toward non-stimulant alternatives. Guanfacine prescriptions have increased as a result, putting unexpected pressure on local supplies.

Increased ADHD diagnoses overall: ADHD diagnosis rates in the U.S. have continued to rise, increasing demand across all ADHD medications.

Strength-specific gaps: Higher-strength ER tablets (3 mg and 4 mg) are ordered less frequently at retail pharmacies and are more prone to localized out-of-stock situations.

Generic manufacturer variability: Different pharmacies source from different generic manufacturers. When one manufacturer has a production delay, the pharmacies that rely on that manufacturer may experience temporary stock-outs.

A Brief History of Guanfacine Availability

Guanfacine has been on the U.S. market since 1986 and has had a generally reliable supply history compared to stimulant medications. When brand-name Intuniv lost patent protection and generics entered the market, overall availability actually improved — more manufacturers mean more supply redundancy.

The current availability challenges are primarily secondary effects of the broader ADHD medication shortage, not the result of a Guanfacine-specific manufacturing crisis.

What the FDA and ASHP Say

Neither the FDA's Drug Shortages Database nor the American Society of Health-System Pharmacists (ASHP) shortage list currently includes Guanfacine as an active shortage. These are the two most authoritative sources for shortage information. If this status changes, both resources will be updated.

If you're experiencing persistent difficulty finding Guanfacine in your area, you can report it to the FDA at drugshortages@fda.hhs.gov. Patient and provider reports help the FDA monitor emerging supply problems before they become formal shortages.

What Patients Should Do Right Now

Even without a formal shortage, it's wise to be proactive. Here's what you can do today:

Refill early — start looking 7–10 days before you run out, not the day you take your last pill.

Use medfinder to find which pharmacies near you have your specific strength in stock.

Consider switching to a mail-order pharmacy for 90-day supplies — it's more convenient and reduces how often you need to manage refills.

If your strength is consistently hard to find, ask your prescriber if a different strength combination could work (e.g., two 1 mg tablets instead of one 2 mg tablet, if that's clinically appropriate).

Never stop Guanfacine abruptly — always contact your prescriber if supply is getting critically low.

Is a Guanfacine Shortage Coming in 2026?

There's no current indication of an imminent Guanfacine national shortage. The medication has multiple generic producers and is not subject to the DEA production quotas that constrain stimulant medications. As long as this remains the case, a formal shortage is unlikely. The main risk continues to be demand-driven localized stock-outs in high-ADHD-diagnosis areas.

Bottom Line for Patients

Guanfacine is generally available in 2026, but pharmacy-level variability means you may need to look beyond your first-choice pharmacy. Plan ahead, use tools to check stock near you, and always keep your prescriber in the loop if supply becomes an issue. And if you need to know what alternatives exist, read our guide: Alternatives to Guanfacine if you can't fill your prescription.